1. Home
  2. ARMK vs NBIX Comparison

ARMK vs NBIX Comparison

Compare ARMK & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aramark

ARMK

Aramark

HOLD

Current Price

$57.18

Market Cap

15.3B

ML Signal

HOLD

Logo Neurocrine Biosciences Inc.

NBIX

Neurocrine Biosciences Inc.

HOLD

Current Price

$175.77

Market Cap

13.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARMK
NBIX
Founded
1959
1992
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.3B
13.2B
IPO Year
2013
1996

Fundamental Metrics

Financial Performance
Metric
ARMK
NBIX
Price
$57.18
$175.77
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
22
Target Price
$47.88
$180.91
AVG Volume (30 Days)
2.4M
1.1M
Earning Date
05-12-2026
05-05-2026
Dividend Yield
1.07%
N/A
EPS Growth
23.23
41.95
EPS
0.74
1.91
Revenue
$18,506,299,000.00
$161,626,000.00
Revenue This Year
$8.71
$24.73
Revenue Next Year
$6.57
$13.14
P/E Ratio
$77.03
$91.18
Revenue Growth
6.35
977.51
52 Week Low
$35.07
$122.14
52 Week High
$58.68
$181.18

Technical Indicators

Market Signals
Indicator
ARMK
NBIX
Relative Strength Index (RSI) 62.17 58.30
Support Level $55.16 $169.01
Resistance Level $58.68 $181.18
Average True Range (ATR) 1.15 4.73
MACD -0.21 -0.58
Stochastic Oscillator 59.89 54.07

Price Performance

Historical Comparison
ARMK
NBIX

About ARMK Aramark

Aramark, founded in 1936 and headquartered in Philadelphia, Pennsylvania, operates as a food service company providing facility management and workplace solutions. The company primarily generates revenue from its North American food and support services segment, serving clients such as schools, healthcare facilities, and entertainment venues.

About NBIX Neurocrine Biosciences Inc.

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

Share on Social Networks: